Maharashtra Man Dies After Getting 2nd Dose Of Covid Vaccine
FILE PHOTO: Sanitation worker Manish Kumar, who according to officials is the first person in the country vaccinated against COVID-19, receives a dose of Bharat Biotech's COVAXIN during the COVID-19 vaccination campaign at the All India Institute of Medical Sciences Hospital in New Delhi on January 16, 2021
A 45-year-old man died shortly after he was administered the second dose of a COVID-19 vaccine in a hospital in Bhiwandi in Maharashtra’s Thane district on Tuesday, officials said.
Sukhdeo Kirdit, employed as the driver of a local doctor, took the shot around 11 AM.
He complained of giddiness after some time while he was seated in the waiting hall at the civic-run inoculation centre, they said.
“He was rushed to IGM Hospital nearby where doctors declared him dead on arrival,” an official said.
Bhiwandi Nizampura Municipal Corporation Health Officer Dr KR Kharat said the cause of Kirdit’s death would be known after the post-mortem report comes in, adding that Kirdit’s medical history, records etc.were being checked.
Kirdit’s family said he was a healthy person who had left home in the morning to take the second dose of the vaccine.
Meanwhile, India’s COVID-19 vaccine produced by Bharat Biotech has shown an interim vaccine efficacy of 81 percent in late-stage clinical trials, the company based in Hyderabad said.
The interim analysis was based on 43 recorded cases of COVID-19 in the trial of 25,800 participants, conducted in partnership with the Indian Council of Medical Research (ICMR) – India’s premier medical research body.
Thirty-six of the 43 cases were recorded in participants who received a placebo, compared with seven cases in people who were given the Bharat Biotech vaccine, pointing to an efficacy rate of 80.6 per cent, the company said on Wednesday.
India had approved the vaccine, branded COVAXIN, in January without late-stage efficacy data, raising questions about its effectiveness.
The vaccination drive in the world’s second-most populous nation, currently under way, includes COVAXIN and a vaccine developed by Oxford University and AstraZeneca, named Covishield.
